Abner Herrman & Brock LLC Buys 75,536 Shares of Johnson & Johnson $JNJ

Key Points

• Abner Herrman & Brock LLC increased its Johnson & Johnson stake by 1,864.2% in the second quarter, adding 75,536 shares for a total holding of 79,588 shares valued at approximately $20.2 million.
• Johnson & Johnson reported quarterly earnings of $2.90 per share and revenue of $25.31 billion, beating analyst estimates, while revenue increased 6.6% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $268.22.
• The company declared a quarterly dividend of $1.34, equivalent to a $5.36 annualized payout and a 2.1% yield. However, insiders sold nearly 49,000 shares worth about $12.3 million in the latest quarter, and the reported $5.5 billion talc settlement remains a significant financial consideration.

Abner Herrman & Brock LLC lifted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 1,864.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 79,588 shares of the company's stock after buying an additional 75,536 shares during the period. Johnson & Johnson makes up approximately 1.9% of Abner Herrman & Brock LLC's holdings, making the stock its 20th largest holding. Abner Herrman & Brock LLC's holdings in Johnson & Johnson were worth $20,213,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Auto Owners Insurance Co increased its holdings in Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Norges Bank bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $6,924,523,000. Capital World Investors bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $2,005,942,000. Diamant Asset Management Inc. increased its stake in shares of Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock valued at $109,338,000 after buying an additional 4,454,778 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock valued at $49,740,362,000 after acquiring an additional 3,731,074 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Bank of America lifted their price target on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a "neutral" rating in a report on Friday, July 10th. JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, April 15th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a research note on Thursday, July 16th. Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Finally, TD Cowen increased their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $268.22.

Johnson & Johnson Stock Up 0.8%

NYSE:JNJ opened at $259.03 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market cap of $624.23 billion, a P/E ratio of 30.01, a P/E/G ratio of 2.45 and a beta of 0.24. Johnson & Johnson has a fifty-two week low of $170.39 and a fifty-two week high of $274.90. The firm has a 50-day simple moving average of $248.47 and a two-hundred day simple moving average of $239.73.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter last year, the firm earned $2.77 earnings per share. The firm's quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts predict that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson's dividend payout ratio (DPR) is currently 62.11%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Dividend appeal remains a key support. Recent coverage highlights JNJ as a blue-chip income stock with a long record of dividend growth and defensive fundamentals, which may attract investors seeking stability amid elevated interest rates. Why is Johnson & Johnson drawing dividend attention today? Top dividend stocks to buy and hold
• Positive Sentiment: Reported talc settlement removes a major legal overhang. JNJ agreed to a reported $5.5 billion settlement covering tens of thousands of talc lawsuits. While costly, resolving the claims could improve legal and financial visibility and reduce uncertainty surrounding the company. Johnson & Johnson reaches $5.5 billion talc settlement
• Positive Sentiment: Citi issued a Buy rating, adding to the favorable analyst backdrop. JNJ’s latest reported quarter also exceeded expectations, with revenue rising 6.6% year over year and earnings surpassing consensus estimates. Johnson & Johnson gets a Buy from Citi
• Neutral Sentiment: Coverage says JNJ has remained steady during a division transition. The company is also investing more than $1 billion to expand U.S. contact-lens production, a potential long-term growth initiative, although near-term returns remain uncertain. Why Johnson & Johnson is steady amid a division transition
• Negative Sentiment: The talc agreement represents a substantial cash and earnings burden, and investors may continue evaluating whether the settlement fully resolves future claims and related costs.

Insiders Place Their Bets

In related news, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the business's stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 48,972 shares of company stock valued at $12,295,205. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source